Cowen & Co. Keeps a Buy Rating on Esperion (ESPR)

By Carrie Williams

Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Esperion (ESPRResearch Report) today and set a price target of $80. The company’s shares closed yesterday at $43.78.

According to, Shibutani is a 4-star analyst with an average return of 7.6% and a 44.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $85.33 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $60.99 and a one-year low of $36.06. Currently, Esperion has an average volume of 523.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Esperion Therapeutics, Inc. operates as a clinical stage pharmaceutical company, which engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C).